#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thrombotic microangiopathy Desmoid tumour Phenylketonuria Autologous haematopoietic stem cell transplant Blastic plasmacytoid dendritic cell neoplasia Skin angiosarcoma Cataract Rheumatoid arthritis Oesophageal atresia Spinal cord injury Behcet's syndrome Chronic graft versus host disease in skin Adenocarcinoma gastric Astrocytoma Pituitary-dependent Cushing's syndrome More trials…

    Learn about Rare Diseases

    Mast cell activation syndrome – Diagnostics Ornithine transcarbamoylase deficiency – Trials in Disease Idiopathic pulmonary fibrosis – Diagnostics Ehlers-Danlos syndrome – Life with Disease Atypical teratoid/rhabdoid tumour of CNS – Life with Disease Atypical teratoid/rhabdoid tumour of CNS – Trials in Disease Lymphangiosarcoma – Trials in Disease Congenital generalised lipodystrophy Splenic marginal zone lymphoma Mucopolysaccharidosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dactinomycin Minocycline Berotralstat Sulodexide Romiplostim Dorzolamide Hydrochloride T89 AZD0516 Oxybuprocaine Fluvastatin MZE829 Arachis Hypogaea Flour Terbinafine Clofutriben Ucp2 Avb-101 Urapidil Fosaprepitant Retinol Acetate Deupirfenidone More therapies…

    Learn about Your Condition

    Anal squamous cell carcinoma Hepatic neoplasm Congenital myopathy Precocious puberty Congenital pseudarthrosis Papillary thyroid cancer Childhood asthma Post procedural oedema Peritoneal dialysis Vaginal infection Niemann-Pick disease Systemic sclerosis pulmonary Retinal neovascularisation Electronic cigarette user Sinus rhythm More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

B-cell lymphoma refractory

  • Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

    Recruiting

    2 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Valemetostat Tosilate
    Belgium France

  • Study on the Safety and Effectiveness of MB-CART2019.1, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory B Cell Neoplasms

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Zamtocabtagene Autoleucel
    • Cyclophosphamide
    • Tocilizumab
    France Germany Italy The Netherlands

  • Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Zamtocabtagene Autoleucel
    • Bendamustine Hydrochloride
    • Gemcitabine Hydrochloride
    Austria Belgium Croatia Czechia Finland France +9

  • Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

    Recruiting

    1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    Investigated Drugs:
    • Mb-Cart20.1
    • Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
    • Zamtocabtagene Autoleucel
    Germany

  • Study on UCART20x22 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Using a Drug Combination

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Alemtuzumab
    • Ucart20X22
    • Aldesleukin
    France Italy Spain

  • Study of MEN1703 and Glofitamab for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

    Recruiting

    2 1 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    Investigated Drugs:
    • 5,6-Dibromo-4-Nitro-2-Piperidin-4-Yl-1-Propan-2-Ylbenzimidazole
    • Glofitamab
    • Obinutuzumab
    France Poland Spain
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!